We thus measured ARG1 levels in the plasma samples obtained from 64 glioma patients (15 GII, 10 GIII and 39 GIV) and found that ARG1 levels in glioma patients were significantly higher compared to HD control (Figure 2L). This evidence concerns the gene ARG1 and central nervous system cancer.